To clarify the clarification, Omapro is for patients that fail treatment with tyrosine kinase inhibitors, including Gleevec, nilotonib and Sprycel, due to the T3151 mutation. Omapro is the only alternative to TKI's in that situation.
Omapro uses a different mechanism to TKI's.
Re risk, do you know whether omapro is more or less of a health risk than, say, Gleevec?
To clarify the clarification, Omapro is for patients that fail...
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)